Optimal conditions required for influenza A infection-enhanced cross-priming of CD8+ T cells specific to cell-associated antigens

Immunology and Cell Biology

Volumn 91, Issue 9, 2013, Pages 576-582

  Wei, Joe ^a   Waithman, Jason ^b   Xiao, Kun ^c   Oveissi, Sara ^c   Chen, Weisan ^c  

^a LUDWIG INSTITUTE FOR CANCER RESEARCH   (Australia)

^b UNIVERSITY OF WESTERN AUSTRALIA   (Australia)

^c LA TROBE UNIVERSITY   (Australia)

Author keywords

cross priming; influenza A virus; melanoma; tumour

Indexed keywords

B16.MOVA.PR8; CANCER VACCINE; CELL ANTIGEN; UNCLASSIFIED DRUG;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CD8+ T LYMPHOCYTE; CONTROLLED STUDY; CROSS PRESENTATION; DENDRITIC CELL; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA A; INFLUENZA VIRUS A; MELANOMA; MOUSE; NONHUMAN; TUMOR IMMUNITY;

INFLUENZA A VIRUS;

ANIMALS; ANTIGENS, NEOPLASM; BYSTANDER EFFECT; CANCER VACCINES; CD8-POSITIVE T-LYMPHOCYTES; CELLS, CULTURED; CROSS-PRIMING; DENDRITIC CELLS; INFLUENZA A VIRUS; MELANOMA, EXPERIMENTAL; MEMBRANE PROTEINS; MICE; MICE, INBRED C57BL; NEOPLASM TRANSPLANTATION; ORTHOMYXOVIRIDAE INFECTIONS;

EID: 84885479286     PISSN: 08189641     EISSN: 14401711     Source Type: Journal    
DOI: 10.1038/icb.2013.46     Document Type: Article

References (35)

1. Akira S, Takeda K. Toll-like receptor signalling. Nat Rev Immunol 2004; 4: 499-511. (Pubitemid 38931765)
2. Kavanagh B, Ko A, Venook A, Margolin K, Zeh H, Lotze M et al. Vaccination of metastatic colorectal cancer patients with matured dendritic cells loaded with multiple major histocompatibility complex class I peptides. J Immunother 2007; 30: 762-772. (Pubitemid 47480759)
3. Medzhitov R. Origin and physiological roles of inflammation. Nature 2008; 454: 428-435.
4. Heath WR, Carbone FR. Cross-presentation, dendritic cells, tolerance and immunity. Annu Rev Immunol 2001; 19: 47-64. (Pubitemid 32368029)
5. Melief CJ. Mini-review: regulation of cytotoxic T lymphocyte responses by dendritic cells: peaceful coexistence of cross-priming and direct priming? Eur J Immunol 2003; 33: 2645-2654. (Pubitemid 37337130)
6. Sotomayor EM, Borrello I, Levitsky HI. Tolerance and cancer: a critical issue in tumor immunology. Crit Rev Oncog 1996; 7: 433-456.
7. Zhou G, Levitsky HI. Natural regulatory T cells and de novo-induced regulatory T cells contribute independently to tumor-specific tolerance. J Immunol 2007; 178: 2155-2162. (Pubitemid 46233413)
8. Durand V, Wong SY, Tough DF, Le Bon A. Shaping of adaptive immune responses to soluble proteins by TLR agonists: a role for IFN-alpha/beta. Immunol Cell Biol 2004; 82: 596-602. (Pubitemid 39563960)
9. Neller MA, Lopez JA, Schmidt CW. Antigens for cancer immunotherapy. Semin Immunol 2008; 20: 286-295.
10. Schulz O, Diebold SS, Chen M, Naslund TI, Nolte MA, Alexopoulou L et al. Toll-like receptor 3 promotes cross-priming to virus-infected cells. Nature 2005; 433: 887-892. (Pubitemid 40314900)
11. + T cells to cell-associated antigens in a TLR7- and type I IFN-dependent fashion. J Immunol 2010; 185: 6013-6022.
12. Shen H, Ackerman AL, Cody V, Giodini A, Hinson ER, Cresswell P et al. Enhanced and prolonged cross-presentation following endosomal escape of exogenous antigens encapsulated in biodegradable nanoparticles. Immunology 2006; 117: 78-88.
13. Hafalla JC, Sano G, Carvalho LH, Morrot A, Zavala F. Short-term antigen presentation and single clonal burst limit the magnitude of the CD8(+) T cell responses to malaria liver stages. Proc Natl Acad Sci USA 2002; 99: 11819-11824. (Pubitemid 34994482)
14. Shen L, Rock KL. Cellular protein is the source of cross-priming antigen in vivo. Proc Natl Acad Sci USA 2004; 101: 3035-3040. (Pubitemid 38327730)
15. Diebold SS, Kaisho T, Hemmi H, Akira S, Reis e Sousa C. Innate antiviral responses by means of TLR7-mediated recognition of single-stranded RNA. Science 2004; 303: 1529-1531. (Pubitemid 38314425)
16. Diebold SS, Montoya M, Unger H, Alexopoulou L, Roy P, Haswell LE et al. Viral infection switches non-plasmacytoid dendritic cells into high interferon producers. Nature 2003; 424: 324-328. (Pubitemid 36899375)
17. + T cells by viral and tumor antigens is a robust phenomenon. Eur J Immunol 2004; 34: 194-199. (Pubitemid 38111535)
18. + T cells stimulated by virus-induced type I interferon. Nat Immunol 2003; 4: 1009-1015. (Pubitemid 37265922)
19. Bachleitner-Hofmann T, Friedl J, Hassler M, Hayden H, Dubsky P, Sachet M et al. Pilot trial of autologous dendritic cells loaded with tumor lysate(s) from allogeneic tumor cell lines in patients with metastatic medullary thyroid carcinoma. Oncol Rep 2009; 21: 1585-1592.
20. Hofman FM, Stathopoulos A, Kruse CA, Chen TC, Schijns VE. Immunotherapy of malignant gliomas using autologous and allogeneic tissue cells. Anticancer Agents Med Chem 2010; 10: 462-470.
21. Chiang CL, Benencia F, Coukos G. Whole tumor antigen vaccines. Semin Immunol 2010; 22: 132-143.
22. + T cell immunodominance during primary influenza infection due to differences in antigen presentation, T cell avidity, and precursor numbers. J Immunol 2013; 190: 36-47.
23. + T cell response. Proc Natl Acad Sci USA 2003; 100: 7235-7240. (Pubitemid 36706422)
24. Shaw ML, Stone KL, Colangelo CM, Gulcicek EE, Palese P. Cellular proteins in influenza virus particles. PLoS Pathog 2008; 4: e1000085.
25. Beloso A, Martinez C, Valcarcel J, Santaren JF, Ortin J. Degradation of cellular mRNA during influenza virus infection: its possible role in protein synthesis shutoff. J Gen Virol 1992; 73 (Pt 3): 575-581.
26. Yewdell JW, Bennink JR, Hosaka Y. Cells process exogenous proteins for recognition by cytotoxic T lymphocytes. Science 1988; 239: 637-640. (Pubitemid 18066227)
27. Yewdell J, Garcia-Sastre A. Influenza virus still surprises. Curr Opin Microbiol 2002; 5: 414-418.
28. Shen Z, Reznikoff G, Dranoff G, Rock KL. Cloned dendritic cells can present exogenous antigens on both MHC class I and class II molecules. J Immunol 1997; 158: 2723-2730. (Pubitemid 127470530)
29. Norbury CC, Hewlett LJ, Prescott AR, Shastri N, Watts C, Class I. MHC presentation of exogenous soluble antigen via macropinocytosis in bone marrow macrophages. Immunity 1995; 3: 783-791. (Pubitemid 26091151)
30. Wilson NS, Behrens GM, Lundie RJ, Smith CM, Waithman J, Young L et al. Systemic activation of dendritic cells by Toll-like receptor ligands or malaria infection impairs cross-presentation and antiviral immunity. Nat Immunol 2006; 7: 165-172. (Pubitemid 43135882)
31. Le Goffic R, Balloy V, Lagranderie M, Alexopoulou L, Escriou N, Flavell R et al. Detrimental contribution of the Toll-like receptor (TLR)3 to influenza A virus-induced acute pneumonia. PLoS Pathog 2006; 2: e53.
32. Le Goffic R, Pothlichet J, Vitour D, Fujita T, Meurs E, Chignard M et al. Cutting Edge: Influenza A virus activates TLR3-dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells. J Immunol 2007; 178: 3368-3372. (Pubitemid 46417600)
33. Thomas PG, Dash P, Aldridge JR Jr., Ellebedy AH, Reynolds C, Funk AJ et al. The intracellular sensor NLRP3 mediates key innate and healing responses to influenza A virus via the regulation of caspase-1. Immunity 2009; 30: 566-575.
34. Hodi FS, O'Day SJ, McDermott DF, Weber RW, Sosman JA, Haanen JB et al. Improved survival with ipilimumab in patients with metastatic melanoma. N Engl J Med 2010; 363: 711-723.
35. Topalian SL, Hodi FS, Brahmer JR, Gettinger SN, Smith DC, McDermott DF et al. Safety, activity, and immune correlates of anti-PD-1 antibody in cancer. N Engl J Med 2012; 366: 2443-2454.